Jennifer Ann Rothman

Journal Article Blood Adv · March 10, 2026 Malignancy-associated hemophagocytic lymphohistiocytosis (mHLH), a hyperinflammatory syndrome, has poor prognosis and no standard therapy. Emapalumab, a fully human monoclonal antibody that neutralizes the proinflammatory cytokine interferon gamma, is appr ... Full text Link to item Cite

Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.

Journal Article JAMA · November 25, 2025 IMPORTANCE: Eltrombopag, a thrombopoietin receptor agonist, is approved by the US Food and Drug Administration for children with chronic immune thrombocytopenia. Efficacy of eltrombopag during the newly diagnosed phase of pediatric immune thrombocytopenia ... Full text Link to item Cite

End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children

Conference Blood · November 3, 2025 AbstractBackground: The Pediatric ITP Newly diagnosed patients Eltrombopag vs Standard therapy (PINES) trial, NCT03939637, was an investiga ... Full text Cite

View All Publications

Recent Grants

A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease

Clinical TrialPrincipal Investigator · Awarded by Novo Nordisk, Inc. · 2025 - 2027

PROTOCOL AG348-C-008 Pyruvate Kinase Deficiency Global Longitudinal Registry

Clinical TrialPrincipal Investigator · Awarded by Agios Pharmaceuticals, Inc. · 2018 - 2027

AG348-C-023

Clinical TrialPrincipal Investigator · Awarded by Agios Pharmaceuticals, Inc. · 2022 - 2027

View All Grants

Education, Training & Certifications

University of Medicine and Dentistry of New Jersey · 2003 M.D.